Hepatitis C virus E2 envelope glycoprotein produced in *Nicotiana benthamiana* triggers humoral response with virus-neutralizing activity in vaccinated mice

Mihaela-Olivia Dobrica¹, André van Eerde², Catalin Tucureanu³, Adrian Onu³, Lisa Paruch², Iuliana Caras³, Ene Vlase³, Hege Steen², Sissel Haugslien², Dominic Alonzi⁴, Nicole Zitzmann⁴, Ralph Bock⁵, Jean Dubuisson⁶, Costin-Ioan Popescu¹, Crina Stavaru³*, Jihong Liu Clarke²*, Norica Branza-Nichita¹*

¹Institute of Biochemistry of the Romanian Academy, Bucharest, Romania. ²NIBIO - Norwegian Institute of Bioeconomy Research, Ås, Norway. ³“Cantacuzino” Medico-Military National Research Institute, Bucharest, Romania. ⁴Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford, United Kingdom. ⁵Max Planck Institute of Molecular Plant Physiology, Potsdam-Golm, Germany. ⁶Université Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France

* Corresponding authors:
Dr. Norica Nichita, Institute of Biochemistry of the Romanian Academy, Splaiul Independentei 296, Sector 6, Bucharest, Romania, Email: nichita@biochim.ro; phone: 00-40-0212239069, orcid.org/0000-0001-7896-7930;
Dr. Jihong Liu Clarke, NIBIO- Norwegian Institute of Bioeconomy Research, P.O. Box 115, N-1431 Ås, Norway, Email: jihong.liu-clarke@nibio.no
Dr. Crina Stavaru, “Cantacuzino” Medico-Military National Research Institute, Bucharest, Romania, Email: stavaru34@yahoo.com

Running title: HCV envelope glycoproteins expression in *Nicotiana benthamiana*

Key words: plant biopharmaceuticals, HCV vaccine, E2 glycoprotein, N-glycosylation, HCV neutralizing antibodies.

Word count: 7000

Summary

Chronic infection with hepatitis C virus (HCV) remains a leading cause of liver-related pathologies and a global health problem, currently affecting more than 71 million people worldwide. The development of a prophylactic vaccine is much needed to complement the effective antiviral treatment available and achieve HCV eradication. Current strategies focus on increasing the immunogenicity of the HCV envelope glycoprotein E2, the major target of virus neutralizing antibodies, by testing various expression systems or manipulating the protein conformation and the N-glycosylation pattern.

Here we report the first evidence of successful production of the full-length HCV E2 glycoprotein in *Nicotiana benthamiana*, by using the *Agrobacterium*-mediated transient expression technology. Molecular and functional analysis showed that the viral protein was correctly processed in plant cells and achieved the native folding required for binding to CD81, one of the HCV receptors. N-glycan analysis of HCV-E2 produced in *N. benthamiana* and mammalian cells indicated host-specific trimming of mannose residues and possibly, protein trafficking. Notably, the plant-derived viral antigen triggered a significant immune response in vaccinated mice, characterized by the presence of antibodies with HCV neutralizing activity. Together, our study demonstrates that *N. benthamiana* is a viable alternative to costly mammalian cell cultures for the expression of complex viral antigens and supports the use of plants as cost-effective production platforms for development of HCV vaccines.
Key words: plant biopharmaceuticals, HCV vaccine, E2 glycoprotein, N-glycosylation, HCV neutralizing antibodies.

Introduction

Hepatitis C Virus (HCV), a Hepacivirus member of the Flaviviridae family of enveloped RNA viruses, is a major human pathogen, currently affecting more than 71 million individuals worldwide (WHO, 2019). Chronic infection leads to severe liver damage, cirrhosis and hepatocellular carcinoma (HCC) and eventually death (Levrero, 2006). The new curative, all-oral direct-acting antivirals (DAAs) treatments for HCV have been met with enthusiasm due to their simplicity of administration, efficiency in more than 90% of treated patients and cross-genotypic effect (Gonzalez-Grande et al., 2016; Pawlotsky, 2014). Despite these remarkable results, the DAAs therapy is still costly, which makes it less accessible in low income countries confronted with highest HCV infection rates, and does not confer immunity to patients who have cleared the pathogen. The development of a prophylactic vaccine would not only fill these gaps, but would clearly complement current treatments towards the ultimate goal of HCV eradication. Due to the high mutation rate of the viral RNA genome, production of an efficient HCV vaccine remains challenging. Nevertheless, accumulating evidence indicates that a strong humoral immune response inducing virus-neutralizing antibodies (nAbs) early in infection, contributes significantly to HCV clearance (Osburn et al., 2014; Walker et al., 2019). Most of these nAbs are directed against the E2 glycoprotein, one of the two HCV surface proteins spanning the lipid bilayer of the viral envelope (Pierce et al., 2016), making this protein a promising B-cell based vaccine candidate. Therefore, many experimental strategies have focused on increasing the E2 glycoprotein immunogenicity and its ability to elicit cross-genotype nAbs. These approaches include recombinant expression in various hosts, removal of hypervariable domains, truncations and manipulation of the redox status or of the N-glycan pattern (Fenouillet et al., 2008; Heile et al., 2000; Urbanowicz et al., 2019).

We have recently reported the successful production of an immunogenic HCV E1E2 heterodimer in Lactuca sativa, demonstrating the feasibility of using plants as expression systems for complex transmembrane glycoproteins, whose synthesis requires extensive co- and post-translational maturation steps (Clarke et al., 2017). While plant cells possess a similar protein folding
machinery and have the ability to carry out similar post-translational modifications as mammalian cells, production of recombinant proteins in plants is more cost-effective, easier to scale up and not prone to contamination with potentially harmful animal pathogens (Bock, 2015; Chan and Daniell, 2015; Chan et al., 2016; Clarke and Daniell, 2011). Successful production of human therapeutics such as the ZMapp™ cocktail of anti-Ebola antibodies, which proved its clinical utility during the recent Ebola outbreak, has illustrated the potential of plant molecular farming (Qiu et al., 2014).

In this study, we have explored the potential of *N. benthamiana* as a suitable host for the production of the HCV E2 glycoprotein, the current HCV vaccine candidate, by using our established agroinfiltration facility (Clarke et al., 2017; van Eerde et al., 2020). Production of biopharmaceuticals in *Nicotiana* (tobacco) species has several key advantages over other plant-based expression systems. As tobacco is a non-food, non-feed crop, the regulatory requirements for the production of recombinant proteins are less cumbersome (Schillberg et al., 2019). In addition, the vacuum infiltration-based transient expression system permits recombinant protein accumulation exclusively in the leaves (thus preventing expression in reproductive tissues). Plants are safely discarded after harvest of the leafy biomass, and in this way, unwanted seed-based transgene dispersal can be excluded (Clarke et al., 2017).

Our work provides the first evidence of efficient production of the HCV E2 glycoprotein in *N. benthamiana*. We show that the viral protein is correctly processed in plant cells and acquires the native conformation required for specific binding to CD81, a critical receptor involved in HCV entry into hepatocytes (Feneant et al., 2014; Pileri et al., 1998). Interestingly, sequencing of the E2 N-linked glycans revealed subtle differences in mannose trimming between mammalian and plant-expressed protein. Mice vaccination with the E2 antigen purified from *N. benthamiana* leaves triggered a robust systemic immune response characterized by the early presence of anti-HCV IgM antibodies followed by isotype maturation to IgG. Most importantly, the presence of nAbs against the homologous HCV isolate was demonstrated, supporting deployment of plants as cost-effective production platform for HCV vaccines.

**Results**

**Production of the HCV-E2 antigen in *N. benthamiana* and HEK 293T**
To investigate whether *N. benthamiana* is a suitable host for production of the HCV E2 glycoprotein, a vector containing the E2 antigen for use in transient *Agrobacterium*-mediated expression was designed (Figure 1a). As a reference system for the plant-produced E2, the viral glycoprotein was also produced in HEK293T cells. During infection, the viral genome is translated into a single polyprotein that is processed by cellular and viral proteases into individual structural and non-structural proteins (Penin et al., 2004; Reed and Rice, 2000). The E1 and E2 envelope proteins are translocated across the endoplasmic reticulum (ER), where the C-terminal part of E1 forms a transmembrane helix enabling initiation of E2 translocation. Both E1 and E2 are then released from the polyprotein following cleavage by the ER-resident signal peptidase (Cocquerel et al., 2000). Therefore, to ensure proper ER localization of HCV E2 when expressed alone, the coding sequence of E2 was preceded by the last 32 codons of E1 in our expression vector. This preceding sequence was designed to act as a signal sequence and is expected to be removed by processing by the host signal peptidase, to produce mature full-length E2. Indeed, HEK 293T cell transfection with plasmids encoding either the E1E2 polyprotein (phCMVdeltaC-E1E2) or the N-terminally extended E2 (pcDNA3-E2), followed by immunoblotting showed a band at the predicted molecular weight of the fully-glycosylated, mature E2 protein of about 70 kDa (Shimotohno et al., 1995) (Figure 1b, left panel). The sequence coding for the N-terminally extended E2 was therefore introduced into a plant expression vector of the pEAQ series (Figure 1a), and used in agroinfiltration of *N. benthamiana* leaves. A side-by-side immunoblot analysis of agroinfiltrated *N. benthamiana* leaves and transfected HEK293T cell extracts revealed a slightly lower electrophoretic mobility of HCV-E2 produced in in the former system (Fig 1b, right panel). The strong signal detected in the tobacco system suggests that the E2 protein alone can be successfully produced in *N. benthamiana* using this expression strategy.

**Molecular characterization of the HCV-E2 antigen produced in *N. benthamiana* leaves** The observed difference in the electrophoretic mobility of the E2 protein between the two expression systems (Figure 1b, right panel) could be the result of different N-glycosylation/N-glycan processing or, alternatively, impaired processing of the E2 signal sequence in plant cells. To distinguish between these possibilities, mammalian and plant samples were subjected to Endo H digestion prior to western blot analysis (Figure 2). This enzyme cleaves between the first two N-acetylglucosamine residues of N-linked high-mannose type oligosaccharides and is often used to monitor protein trafficking along the secretory pathway (Freeze and Kranz, 2010). Endo H
digestion generated a band of ~40 kDa, the expected molecular weight of the E2 polypeptide, in both samples. This finding indicates faithful removal of the ER signal sequence from E2 also in the tobacco expression system (Figure 2, + samples). Susceptibility to Endo H hydrolysis also points to an ER-specific, high-mannose glycosylation pattern, as this endoglycosidase does not remove mammalian or plant-specific complex N-linked sugars following their transformation in Golgi. This pattern is the result of sequential trimming of the Man$_9$GlcNAc$_2$ glycan precursor attached to the proteins by the ER-resident α1,2-mannosidases, generating smaller N-glycans that contain five to eight mannose residues. Upon leaving the ER, these glycans are further trimmed to complex structures by the ER-Golgi Intermediate Compartment (ERGIC) and Golgi glycosyltransferases (Schwarz and Aebi, 2011). HCV E2 is a highly glycosylated protein, with 11 N-linked glycans accounting for about half of its molecular weight (Goffard et al., 2005). Therefore, the E2 mobility observed upon SDS-PAGE is likely the consequence of mannose residues being trimmed with different efficiency in mammalian as compared to plant cells, a hypothesis that we investigated further by performing N-glycan sequencing.

**Purification of the HCV-E2 antigen from *N. benthamiana***

The E2 protein was purified from plant leaf extracts by GNA affinity chromatography (Figure 3a), followed by size-exclusion chromatography (SEC). The electrophoretically separated proteins in the plant extract are also shown by Coomassie staining in Figure 3a (left panel). Fractions containing the antigen were eluted from SEC as a major peak, as shown by SDS-PAGE under denaturing conditions and western blot analysis with anti-E2 antibodies (Figure 3b). The total elution volume corresponded to that of the 158 kDa calibration marker, suggesting antigen association into dimers. Samples were concentrated by ultrafiltration and tested again by western blot analysis to verify stability of the purified protein. This analysis revealed the presence of a major band at ~75 kDa for the E2 purified from *N. benthamiana* and confirmed the higher apparent molecular weight as compared to the mammalian cell-produced counterpart (Figure 3c). Importantly, there was no evidence of E2 proteolysis during purification from tobacco leaves and mammalian cells, indicating similar stability of the viral antigen, regardless of the expression system.

HCV-E2 quantification in *N. benthamiana* extracts indicated expression levels varying between 5 and 20 µg/g FW, most likely reflecting variable efficiency of agroinfiltration in different leaf areas.
(Figure 3d). Total protein and viral antigen quantification revealed good recovery yields after affinity chromatography and SEC, respectively, and a final antigen purity reaching ~25% (Figure 3d), which was further confirmed by Coomassie staining of gel electrophoretically separated samples (Figure 3c, left panel). However, protein concentration by ultrafiltration (on Amicon-50) resulted in a significant loss of the soluble antigen fraction. This behavior is not unusual for transmembrane proteins like HCV-E2, which often require the presence of detergents for maintenance of a soluble, properly folded state, once the proteins are removed from their native membrane environment. Although this loss of material has not impeded the immunology studies, future large-scale application of this purification protocol will require optimization of storage buffers with regard to detergent content, ionic strength and temperature exposure of samples to prevent antigen precipitation.

**HCV-E2 produced in *N. benthamiana* contains less processed N-linked glycans**

To understand whether N-glycosylation bears host-specific features that contribute to the different apparent molecular weights of the HCV-E2 proteins produced in plant versus mammalian cells, we carried out side-by-side N-glycosylation analysis of the purified viral antigens obtained in the two expression systems. The composition of N-linked glycans released from E2 by enzymatic digestions with PNGase F and Endo H was determined by NP-HPLC (Figure 4 a,b). As expected for ER-resident proteins, only oligomannose glycoforms were identified on HCV-E2. However, whereas Man\(_9\) species were virtually undetectable in HEK293-F–derived samples, a significant proportion of unprocessed glycans was found in the case of the *N. benthamiana*-expressed antigen, as indicated by quantification of the corresponding peaks in extracted chromatograms (Figure 4c, d). Conversely, highly processed Man\(_4\)-Man\(_5\) oligosaccharides are ~3-fold more abundant on E2 produced in mammalian cells as compared to plants. Therefore, the shift observed in the electrophoretic mobility of E2 produced in the two expression hosts (Figures 1b and 2) is likely due to the different extent of N-glycan trimming, and, in particular, by the presence of higher amounts of underprocessed glycans on the *N. benthamiana*-derived antigen.

**HCV-E2 is expressed in native conformation in *N. benthamiana***

HCV attachment to CD81 is mediated by a highly conserved E2 region, spanning amino acid residues 412 to 423 (Owsianka et al., 2001). This sequence is the main target of antibodies
neutralizing HCV upon infection, of which AP33 and 3/11 have been extensively characterized both in vitro and in animal studies (Desombere et al., 2016; Flint et al., 1999; Owsianka et al., 2005). Acquisition of the E2 native conformation is crucial for exposure of the CD81-binding domain and efficient interaction with the large extracellular loop (LEL) of the HCV receptor. Therefore, to assess the folding state of the tobacco-produced HCV-E2, CD81 (LEL)-E2 binding assays were carried out (Clarke et al., 2017; Pileri et al., 1998). The plant-purified E2 strongly interacted with both CD81 and 3/11 anti-E2 antibodies, as revealed by capture ELISA (Figure 5). Moreover, E2 binding to CD81 was significantly inhibited by 3/11 antibodies, confirming the specificity of the interaction. The lack of 3/11 antibody reactivity with the CD81-unbound E2 further verified the quantitative E2 binding to CD81. The results were confirmed in independent CD81 pull-down experiments performed at different E2 purification steps, followed by western blot analysis. Notably, while CD81 efficiently bound the GNA-eluted E2 (i.e., prior to protein concentration), sample dialysis against diluted PBS resulted in complete loss of the ability of E2 to interact with CD81, suggesting conformational changes of the viral antigen (Figure S1). Moreover, vacuum concentration of dialyzed samples had a significant impact on E2 solubility in that only a small protein fraction was recovered in a soluble state, even after heat-treatment with SDS-PAGE sample buffer under reducing conditions. Altogether, the results demonstrate that HCV E2 is produced in a functional conformation in N. benthamiana and highlight the importance of external factors during processing influencing its native folding and solubility.

N. benthamiana-derived HCV-E2 protein triggers a specific humoral response in vaccinated mice

To determine the humoral immune responses elicited in mice vaccinated with N. benthamiana-derived HCV-E2, serum samples collected prior immunization (day 0) and at days 27 and 49 post-immunization were evaluated for the presence of E2-specific IgM and IgG by ELISA. Serum samples collected at day 27 (after two antigen administrations; see Experimental Procedures) showed a significant increase of the IgM titer, which slowly declined by day 49 (Figure 6a). Conversely, the small IgG titer at day 27 increased significantly by day 49 (i.e., after completion of the immunization schedule by the third antigen administration), indicating B-cell activation and maturation (Figure 6b). IgG is the main Ab isotype associated with HCV neutralization. Virus clearance appears to depend on the envelope-specific IgG subclasses developing early in HCV-infected patients (Walker et al., 2020). Therefore, to gain insight into the characteristics of the
IgG-based immune response triggered by vaccination with the plant-derived antigen, mice sera were further tested for the presence of E2-specific IgG subclasses. The analysis revealed significant titers of the IgG1 subclass as detected by ELISA (Figure 6c).

**N. benthamiana**-derived HCV-E2 induces antibodies with HCV-neutralizing activity

Sera from mice vaccinated with **N. benthamiana**-derived E2 (1:25 dilution) were further tested for the presence of nAbs against the homologous HCV isolate by using a luciferase-based HCVpp neutralization assay. The values obtained were normalized to those of the pooled pre-immune sera (day 0) corresponding to the groups of animals immunized with the HCV antigen or **N. benthamiana** background proteins (control), respectively. Remarkably, sera from all mice in the E2-vaccinated group displayed inhibition of HCVpp infection (Figure 7a), with the inhibition being statistically significant when compared to the control group. The HCV nAb AP33 was included in the experiment to control for the specificity of HCVpp neutralization. The results indicated efficient inhibition of HCVpp infection by AP33, as demonstrated before (Desombere et al., 2016). To investigate the specificity of the response against HCV, we have also tested the same serum dilution (1:25) against Vesicular Stomatitis Virus (VSV), an unrelated virus with broad cell tropism (Bartosch et al., 2003), using the same approach. The results indicate no inhibition of VSV-Gpp infection in the presence of the immune sera (Figure 7b).

**Discussion**

The development of a B cell-based vaccine has remained an unmet goal of HCV preventive therapies. Apart from the genetic diversity inherent to RNA viruses, the intrinsic structural features and low immunogenicity of the viral envelope proteins are additional complicating factors that contribute to the limited success of all efforts to produce such a vaccine. Previous studies have indicated that manipulating E2 N-glycosylation by removing N-glycans that shield key epitopes (Falkowska et al., 2007; Helle et al., 2007), or producing truncated (soluble) forms of the envelope glycoproteins in hosts with distinct N-glycosylation pathways (Grzyb et al., 2016; Li et al., 2016; Urbanowicz et al., 2019) improves protein antigenicity. However, whether or not these
changes significantly increase production of broadly neutralizing Abs is still a matter of debate (Urbanowicz et al., 2019).

In this work, we have successfully expressed the full-length HCV-E2 in *N. benthamiana*. As cost-effective, carbon-neutral factories, plants are attractive platforms for the production of biopharmaceuticals, vaccines and other high-value bioproducts using advanced biotechnological tools. During the past decades, considerable efforts have been made towards using plants as production hosts for vaccines against diseases such as Alzheimer’s disease (Ishiura and Yoshida, 2019), cancer (Wong-Arce et al., 2017), dengue fever (van Eerde et al., 2019), hepatitis B (Dobrica et al., 2017; Fedorowicz-Stronska et al., 2016; Pniewski et al., 2018) or poliomyelitis (Chan et al., 2016). However, the immunogenicity of plant-made antigens varies considerably, and can be influenced substantially by the plant-specific protein glycosylation.

The HCV-E2 protein expressed in *N. benthamiana* displayed Endo H-sensitive, high-mannose glycans, suggesting that the transmembrane domain functioning as an ER-retention signal in mammalian cells (Cocquerel et al., 1998) may work similarly in plants. Comparison of the N-glycans attached to E2 proteins produced in plant leaves and mammalian cells revealed interesting features that may indicate host-dependent mannose trimming occurring in the ER (Figure 4). This is not surprising, since removal of the terminal α1,2-linked mannose residue on the internal (B) branch of the Man$_9$GlcNAc$_2$ precursor by the ER-resident α-mannosidase I is the last conserved step of the N-glycosylation pathway in yeast, plants and mammals (Liebminger et al., 2009; Montero-Morales and Steinkellner, 2018). In plants, MNS3 is the only α-mannosidase that has been shown to efficiently perform this enzymatic activity and generate the Man$_8$GlcNAc$_2$ oligosaccharide (Liebminger et al., 2009; Strasser, 2016). This glycan undergoes further mannose trimming by the Golgi-resident α-mannosidases MNS1 and MNS2 on proteins destined for secretion (Liebminger et al., 2009; Strasser, 2016). Notably, ERManI, the mammalian MNS3 orthologue, is mainly localized in ER quality control vesicles (ERQCVs), consistent with its function in early N-glycan processing and the central role it plays in glycoprotein folding and ER-associated protein degradation (ERAD) (Benyair et al., 2015). By contrast, MNS3 is not involved in the ERAD of plant glycoproteins (Huttner et al., 2014) and instead, appears to reside in cis-Golgi compartments, as shown in a recent study performed in *Arabidopsis thaliana* (Schoberer et al., 2019). Therefore, in order to undergo mannose processing by MNS3, ER-resident proteins must cycle between the ER and the cis-Golgi (Schoberer et al., 2019). In mammalian cells, the
transmembrane domain of HCV E2 determines the localization of the protein in the ER by retention rather than recycling, as cis- and medial-Golgi specific Man₄-Man₅ glycans were not identified for HCV E1 and E2 proteins when expressed in hepatic cells (Cocquerel et al., 1999; Duvet et al., 1998). It appears likely that the advanced mannose trimming observed for E2 when expressed in HEK FreeStyle 293 cells is the result of protein overexpression that pushes a fraction of the protein down the secretory pathway and exposes it to processing by Golgi mannosidases. Interestingly, plant ER-resident glycoproteins are characterized by the presence of large amounts of Man₈GlcNAc₂ glycans and the lack of downstream mannose processing (Pagny et al., 2000). However, HCV-E2 produced in N. benthamiana contains a significant pool of Man₆-Man₇ oligosaccharides, possibly suggesting that the intrinsic structural properties of the viral protein favor longer retention in this compartment. Alternatively, the E2 transmembrane domain may allow for protein recycling between cis Golgi and the ER in plant cells. More detailed investigation of the intracellular localization of the HCV-E2 protein in plants is needed to clarify the exact N-glycan composition in relation to antigen protein trafficking along the secretory pathway.

Whether or not the tobacco-specific N-glycan processing imparts the HCV-E2 antigen with improved immunogenic properties, as compared to other expression systems investigated so far, remains to be determined. Nevertheless, mice vaccination with the plant-derived E2 has triggered a vigorous early humoral immune response characterized by the presence of high IgM titers, followed by isotype maturation to IgG, mostly of the IgG1 subclass. Accumulating evidence indicates that the pattern of the immune responses during natural viral infections, particularly the induction of IgG subclasses, strongly influence the outcome of the disease. In HIV-infected patients, an IgG3-predominant response against the envelope glycoproteins was associated with reduced virus titers and significant virus neutralization activity (Cavacini et al., 2003). Similarly, sera of patients recovering from hepatitis B infections contain free IgG Abs targeting the envelope proteins, which belong to the IgG1 and IgG3 subclasses (Rath and Devey, 1988). In the case of HCV infection, characterization of the early immune response has been hampered by the absence of patients seeking medical care at the initial, asymptomatic stages of the disease. One of the few prospective cohort studies performed in newly infected HCV patients indicated that individuals who clear the viral infection have significant anti-E2 IgG1 and IgG3 titers and negligible amounts of IgG2 and IgG4 Abs (Walker et al., 2020). Remarkably,
coexistence of IgM and IgG responses, correlating with increased virus-neutralizing activity was observed in sera of HCV clearers (Walker et al., 2020). The IgM and IgG pattern induced by vaccination with the tobacco-derived E2 may thus explain the robust HCV-neutralizing activity, despite much lower amounts of antigen and fewer boosts being used in this study, as compared to other reports investigating E2 antigens produced in different expression hosts (Urbanowicz et al., 2019).

Taken together, our results provide the first proof that *N. benthamiana* is a suitable host for the expression of functional HCV-E2. So far, production of HCV envelope glycoproteins in plants has only been reported for lettuce (*L. sativa*). However, the rather modest protein yields obtained for the E1E2 heterodimer of only ~90 ng /g leaf fresh weight has prevented further purification and parenteral administration in vaccination studies (Clarke et al., 2017). By contrast, using a similar *Agrobacterium*-mediated, transient expression approach as in *L. sativa*, we achieved a 100-fold increase of HCV-E2 production in *N. benthamiana*. Notably, these amounts are similar to those reported for the hepatitis B surface antigens (HBsAg) obtained in this plant by applying the same methodology (Dobrica et al., 2017). Unlike HBsAg, the HCV E2 protein is not able to form virus-like particles (VLPs) in any expression system used to date (Masavuli et al., 2017). Together, these observations suggest that *N. benthamiana* might possess a higher capacity for recombinant protein synthesis and/or provide a more appropriate milieu for folding and assembly of complex viral proteins, regardless of their assembly state. Together with the fast growth rate and the high biomass produced by tobacco plants, this argues for tobacco as a preferred host in molecular farming for vaccine proteins. There is clearly potential for further improvement of HCV antigen expression in plants. In the present study, we have used non-replicating vectors for transient expression by agroinfiltration. Previous work has shown that agroinfection of plants with viral replicons can substantially boost transient protein expression levels (Gleba et al., 2007; Marillonnet et al., 2005). Similarly, geminivirus-derived DNA replicons can be tested for their potential to enhance transient expression levels through transgene amplification (Huang et al., 2009). Future studies will also address the optimization potential of the purification process, by fusion of the viral antigens with plant-specific signal sequences for more efficient ER translocation, addition of tags to increase solubility and aid purification.

Recently, the first RNA-based vaccines have been commercialized and proved to be highly effective in combating the COVID-19 pandemic. However, conventional vaccines based on recombinant proteins remain of high interest due to their ability to elicit high levels of virus
neutralizing antibodies, as recently shown for the CoV-RBD219N1 vaccine candidate in preclinical trials (Hotez et al., 2020). In this respect, plants have already proved their potential as flexible platforms for rapid production of the SARS-CoV-2 receptor, the angiotensin-converting enzyme 2 (ACE2) that can be used both for therapeutic purposes or vaccine development (Siriwattananon et al., 2020). Also, an oral administration of ACE2 produced in edible plants is expected to trigger a mucosal immune response that is likely needed to prevent SARS-CoV-2 infection at the viral entry sites (Daniell et al., 2021). In addition, it is worth mentioning that, in their chloroplasts, plants can accumulate large amounts of foreign RNA, including long double-stranded RNAs (He et al., 2020), suggesting that plants could also be used as factories for large-scale RNA production for the synthesis of RNA-based vaccines.

Experimental procedures

Mammalian cell lines and plasmids

HEK293T cells (European Collection of Animal Cell Culture, Porton Down, UK) were grown as described (Lazar et al., 2017). FreeStyle 293-F cells (Thermo Scientific) were grown in FreeStyle 293 Expression Medium (Thermo Scientific), using 500 mL Erlenmeyer flasks with 0.2 μm vent caps (Corning), in an incubator at 37°C, 8% CO₂ and shaking at 135 rpm. Huh7 cells (Bartosch et al., 2003) were maintained in DMEM (Dulbecco’s Modified Eagle Medium) (1X) with GlutamaxTM-I (Life Technologies) supplemented with 10% FBS (Fetal Bovine Serum) (Life Technologies) and 1% Non-essential Amino Acids 100X (Life Technologies).

The plasmid pcDNA3-E2 encoding the full length HCV-E2 preceded by a 32 codon sequence corresponding to the C-terminal part of E1, and the plasmid phCMVdeltaC-E1E2 encoding the wild-type E1E2 polypeptide have been described elsewhere (Bartosch et al., 2003). Both HCV sequences are genotype 1a, isolate H77.

Expression of HCV-E2 antigens in mammalian cells

HEK293T cells were transiently transfected with plasmids encoding HCV-E2 and E1E2, by using polyethylenimine, as previously described (Clarke et al., 2017). The HCV-E2 protein was also produced in FreeStyle 293-F cells, by using the FreeStyle 293 Expression System (Thermo Scientific), according to the manufacturer’s protocol. A volume of 200 mL suspension culture of FreeStyle 293-F cells containing 1.2 x 10⁶ cells/mL was transfected with 200 μg pcDNA3-E2 and

This article is protected by copyright. All rights reserved
200 μL FreeStyle MAX transfection reagent. The cells were harvested 4 days post-transfection and pelleted by centrifugation at 10,000x g, for 10 min, at 4°C.

**Construction of a HCV E2 plant expression vector**

The coding region corresponding to the last 32 codons of E1 and the E2 sequence was excised from the pcDNA3-E2 vector and inserted into the plant transient expression vector pEAQ-HT-DEST1 (Sainsbury et al., 2009), using Gateway cloning, essentially as described previously (Clarke et al., 2017). Briefly, attB1 and attB2 recombination sites flanking the coding region were generated by PCR using primers 5’GGGGACAAGTTTTGTACAAAAAAGCAGGCTATGTGGGGAGTCCTGGCGGG-3’ (forward) and 5’-GGGGACCACTTTGTACAAGAAAGCTGGGTTTACTCCGCTTGGGATATG-3’ (reverse), followed by insertion of the amplified fragment into donor vector pDONR/Zeo. The coding region was then transferred to the destination vector pEAQ-HT-DEST1, generating the pEAQ-HT-DEST1/E2 expression vector.

**Transient expression of HCV-E2 antigens in N. benthamiana leaves**

The plant expression vector pEAQ-HT-DEST1/E2 was introduced into ElectroMAX Agrobacterium tumefaciens strain LBA4404 (Invitrogen, USA) by electroporation, as described before (Clarke et al., 2017). Subsequently, the pEAQ-HT-DEST1/E2-containing Agrobacterium cells were cultured and prepared for infiltration as published (Sainsbury et al., 2009; Saxena, 2016). For agroinfiltration, six-week-old N. benthamiana plants grown in a growth chamber under a photoperiod of 16 h light and 8 h dark at 22°C were used. Agroinfiltration was performed with a 2 mL syringe without needle on the underside of the leaf. The agroinfiltrated plants were further grown until harvest at 7 days post-infiltration (dpi) in a confined S2 safety level growth chamber under the same light and temperature conditions. N. benthamiana plants transformed with the empty pEAQ-HT-DEST1 vector were used as control in characterization and immunization experiments.

**Protein extraction from HEK293T and FreeStyle 293-F cells**
Transfected cells were lysed in buffer (10 mM Tris-HCl, 2 mM EDTA, 150 mM NaCl, pH 7.5) containing 0.5% Triton X-100 and a mixture of protease inhibitors (Santa Cruz Biotechnology), for 30 min, on ice. Cell lysates were clarified by centrifugation at 10,000x g, for 10 min, at 4°C, and supernatants were used for further analysis.

**Protein extraction from *N. benthamiana* leaves**

Plant leaves were ground in liquid nitrogen and further homogenized in 5 volumes of extraction buffer (0.15 M NaCl, 20 mM Na₂HPO₄, 20 mM sodium ascorbate, pH 7) containing 0.5% Triton X-100 and a protease inhibitor cocktail (Santa Cruz Biotechnology) for 30 min, on ice. Lysates were centrifuged at 1,000xg for 5 min and then clarified by ultracentrifugation at 27,000xg for 15 min. All centrifugation steps were performed at 4°C. The supernatants were collected and used for subsequent analysis.

**Endoglycosidase H (Endo H) treatment**

*N. benthamiana* and HEK293T cell lysates were treated with Endo H (New England Biolabs, UK) to investigate the N-glycosylation pattern of the HCV antigen, according to the protocol provided by the manufacturer, or left untreated, as control. Protein samples were subjected to SDS-PAGE and immunoblotting, as described below.

**SDS-PAGE and western blot analyses**

Plant and mammalian cell lysates were heat-denatured, separated by SDS-PAGE under reducing conditions followed by electroblotting onto PVDF membranes, as described (Clarke et al., 2017). The HCV E2 was detected by overnight incubation of blots with anti-E2 3/11 antibodies (raised in rats, kindly provided by J.A. McKeating, Oxford University, UK) (diluted 1:2,000 in PBS containing 5% nonfat milk and 0.1% Tween) followed by 1 h incubation with goat anti-rat-HRP (Santa Cruz Biotechnology, diluted 1:10,000 in PBS containing 1% nonfat milk and 0.1% Tween). Protein signals were visualized by using a chemiluminescence kit (ECL, Thermo Scientific).

**Purification of the HCV-E2 antigen by affinity and size-exclusion chromatography**

FreeStyle 293-F cell lysates and *N. benthamiana* leaf extracts expressing the E2 protein were applied to a column packed with *Galanthus nivalis* lectin-agarose (GNA) conjugate (Sigma-
Aldrich) (flow rate 3 mL/min), using either the ÄKTA prime or the ÄKTA start protein purification systems (GE Healthcare). The column was washed three times with PBS, then the bound high-mannose, glycosylated proteins were eluted using 0.5 M methyl-α-D-mannopyranoside (Sigma-Aldrich) in PBS (3 mL/min flow rate). Fractions containing E2, as determined by immunoblot analysis with anti-E2 3/11 antibodies, were pooled and concentrated by ultrafiltration using an Amicon MWCO 50 kDa device (Millipore). E2 samples were then loaded onto a SEC HiLoad 16/600 Superdex 200 pg column (GE Healthcare), using the ÄKTA prime or ÄKTA pure protein purification systems. The column was equilibrated in PBS. Following elution with PBS, fractions were checked for the presence of E2 by western blot, pooled and concentrated as above. The total protein concentration was monitored at various purification steps by using the bicinchoninic acid (BCA) assay (Thermo Scientific) and by staining of SDS-PAGE gels with Coomassie Instant Blue (Expedeon).

Quantification of HCV-E2 protein by ELISA
Serial dilutions of a commercial HCV-E2 fragment corresponding to amino acid positions 383-663, genotype 1b (My BioSource, MBS43003) were adsorbed onto 96-well plates (MaxiSorp, Thermo Scientific; 50 µL/well, overnight, at 4°C). The plates were washed three times with PBS + 0.05% Tween, followed by blocking with 5% nonfat milk in PBS, for 1 h, at room temperature (RT). N. benthamiana and mammalian cell extracts and HCV-E2 samples at different purification steps were first adsorbed onto 96-well plates (1 h, RT) previously coated with GNA (250 ng/well, overnight, at 4°C) to remove non-glycosylated background proteins that could interfere with antigen binding, washed and blocked as described above. Plates were washed two times and were further incubated with rat anti-E2 3/11 antibodies at 1:1,000 dilution, for 1 h, at RT. After five washes, plates were incubated with goat anti-rat-HRP antibody for 1 h, at RT, and washed again before addition of the TMB substrate (Bio Rad). The enzymatic reaction was developed for 30 min, stopped by addition of 1 N sulfuric acid and the absorbance at 450 nm was recorded by using a Mithras LB940 plate reader (Berthold Technologies).

Analysis of HCV-E2 binding to CD81 by capture ELISA
A 20 µg/mL PBS solution of the large extracellular loop of the human CD81 (CD81-LEL) fused to glutathione S-transferase (GST) (Bartosch et al., 2003) was adsorbed onto 96-wells white plates (Corning Costar), at 50 µL/well, overnight, at 4°C. The plates were washed three times with PBS

This article is protected by copyright. All rights reserved
with 0.05% Tween 20 and non-specific binding sites were blocked with 5% nonfat milk in PBS, for 1 h, at RT. Plates were further incubated with a PBS solution of the HCV-E2 antigen purified from N. benthamiana leaves (1 µg/mL, 50 µL/well), pre-incubated or not with anti-E2 3/11 antibody (diluted 1:50), for 1 h, at RT, to control for the specificity of HCV-E2 binding to CD81. The plates were washed five times with PBS with 0.05% Tween 20, then incubated with mouse anti-E2 H53 antibody for 1 h (Op De Beeck et al., 2004) (diluted 1:1,000). The plates were washed again as above, incubated for 1h with secondary anti-mouse-HRP antibody (Santa Cruz Biotechnology, diluted 1:10,000), followed by addition of SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific). Luminescence signals were determined as Relative light units (RLU) by using a Mithras LB940 plate reader (Berthold Technologies). In a control experiment, 96-well white plates were coated with 60 µg/mL of anti-E2 3/11 antibody (50 µL/well), overnight at 4ºC. The plates were washed with PBS and blocked with 5% nonfat milk as above, before incubation with either 1 µg/mL (50 µL/well) of HCV-E2 antigen purified from N. benthamiana leaves or the unbound HCV-E2 antigen after adsorption onto CD81-coated wells. A luminescence assay was performed using the same protocol as above. Samples from non-transformed N. benthamiana leaves were used as negative control in both CD81 and anti-E2 3/11 antibody binding assays.

**In-gel deglycosylation of HCV-E2**

E2 samples purified from either N. benthamiana or FreeStyle 293F cells were separated by SDS-PAGE followed by protein staining with InstantBlue (Expedeon). The protein bands at ~70 kDa were excised from the gel, cut in smaller pieces and dehydrated in acetonitrile by vigorous vortexing followed by washing with H$_2$O. These steps were repeated three times, and the dehydrated gel fragments were then incubated with either PNGase F or Endo H (New England Biolabs) overnight, at 37ºC. The reaction solutions were collected and the gel fragments were washed three times with H$_2$O. The new washing solutions were added to the reaction mixture, which was subsequently subjected to speed-vacuum drying, at 35ºC. The dried samples were resuspended in 30 µL H$_2$O. Proteins remaining in the gel fragments were eluted in SDS-PAGE sample buffer and analyzed by western-blot with anti-E2 3/11 antibodies.
Analysis of HCV-E2 N-glycans by 2-aminobenzoic acid (2-AA) labeling and normal phase-high performance liquid chromatography (NP-HPLC)

N-glycans released by in-gel treatment with PNGase F or Endo H were fluorescently labeled by reductive amination with 80 µL of a mixture containing 30 mg/mL 2-AA, 45 mg/mL sodium cyanoborohydride, 4% sodium acetate-tri-hydrate and 2% boric acid in methanol, for 1 h at 80°C. Labeled glycans were purified essentially as described (Caputo et al., 2016), with minor changes. Briefly, the 2-AA-labeled glycans were mixed with 1 mL 97% acetonitrile, flowed by gravity through a Spe-ed Amide-2 SPE column (Applied Separations) and eluted with 1.5 mL H$_2$O. The recovered samples were then loaded onto a Concanavalin A (ConA)-Sepharose 4B (Sigma-Aldrich) packed column and eluted with 1.5 mL 0.5 M methyl-α-D-mannopyranoside. To remove the methyl-α-D-mannopyranoside, the glycans were further separated on graphitized carbon (PGC) SPE columns and eluted with 1 mL 50% acetonitrile containing 0.1% trifluoroacetic acid. Speed-vacuum-dried samples were resuspended in H$_2$O, mixed with one volume acetonitrile and analyzed by NP-HPLC using a TSK gel-amide 80 column on a Waters Alliance 2695 separation system. The in-line 474 fluorescence detector was set at 360 nm (λexcitation) and 425 nm (λemission). Data were processed using the Empower 3 Waters software. Glucose unit (GU) values were determined using a 2-AA-labeled glucose oligomer ladder consisting of partially hydrolyzed dextran (Sigma-Aldrich), and glycan structures were assigned based on GUs as a function of elution time.

Animals and immunization

Groups of five, 6-8-week-old female BALB/c mice, were immunized by intra-muscular (i.m) administration, 3 times, at 14-day interval. On day 0, animal vaccination was performed with a 50 µL PBS suspension containing 5 µg HCV-E2 and 0.25 mg/mL Al(OH)$_3$ (Alhydrogel vac-alu-250 InVivoGen trademark Brenntag Biosector A/S) adjuvant, followed by boosting with 2 µg of antigen on days 14 and 28. The control groups received the same concentrations of N. benthamiana background protein from control leaves (19.2 and 8 µg for prime and boost injections, respectively), formulated with 0.25 mg/mL Al(OH)$_3$ adjuvant or the adjuvant only. Prior to immunization, and on days 27 and 49, serum samples were collected by orbital puncture, centrifuged at 14,000 x g for 10 min and stored at -80°C until further use. Animal experiments
were conducted according to standards set forth in the Council Directive 86/609/EEC and national legislation, and approved by the national designated authority ANSVSA, registration number 488/22.01.2020.

**Quantification of the immune response**

Flat bottom 384-well MediSorp plates (Sigma-Aldrich) were coated with 0.4 μg/mL (20 μL/well) of HEK293T-produced E1E2 antigen in PBS and incubated overnight at 4ºC. After extensive washing with PBS containing 0.05% Tween 20 (Sigma-Aldrich), plates were blocked for 1 h, at RT with PBS containing 5% nonfat dry milk (BioRad) and then washed as before. Six binary dilutions, starting from 1:200, of serum in PBS containing 5% nonfat dry milk were added to the antigen-coated plates (40 μL/well) and incubated for 2 h, at RT. The plates were washed, incubated with HRP-conjugated goat anti-mouse IgM/IgG (Southern Biotech), diluted 6,000-fold or with HRP-conjugated goat anti-mouse IgG1/IgG2a (Southern Biotech) diluted 1,000-fold in PBS containing 5% nonfat dry milk, for 2 h, at RT. Enzymatic reactions were developed following addition of the TMB substrate (R&D Systems), for 20 min at RT then stopped with 20 μL/well of 1 M H₂SO₄. Absorbance was measured at 450 nm using a Tecan Infinite M1000 microplate reader. Normalization across ELISA plates was performed by pooling all the immune sera from day 49 which served as internal standard. Serum pool dilution starting from 1:100 was used as internal standard on each plate and a 4-parameter logistic regression model was fitted to the measured values.

**HCV pseudo-particles (HCVpp) neutralization assay**

HCVpp were obtained by co-transfection of HEK293T cells with murine leukemia virus (MLV) Gag-Pol packaging vector (phCMV-5349), a luciferase-encoding plasmid (pTG126) and phCMVdeltaC-E1E2 (Op De Beeck et al., 2004) in a 1:1:1 ratio, using polyethylenimine and Opti-MEM. To control the specificity of the neutralization, plasmid phCMV-G encoding the Vesicular Stomatitis Virus glycoprotein G (VSV-G) (Bartosch et al., 2003) was included. Owing to the broad VSV tropism, the resulting pseudo-particles (VSV-Gpp) also served as a positive control for successful pseudotyping and infection, while plasmid pcDNA3.1 (Invitrogen) was used as
negative control. Opti-MEM medium was replaced with DMEM 6 h after transfection. The extracellular medium was collected at 48 h post-transfection, cleared by centrifugation at 1,500×g and further filtered through 0.45 µm filters. The supernatants were stored at 4°C for maximum 2 weeks before use. Mice sera collected at 0 and 56 days post-vaccination were heat-inactivated at 56°C, for 30 min, prior to incubation with HCVpp/ VSV-Gpp for 1 h, at 37°C, at 1:25 dilution. Pre-immune mice sera (day 0) were pooled for each group of animals. Huh7 cells seeded in 48-well plates were inoculated with 250 µL/well HCVpp or VSV-Gpp treated or not with vaccinated mice sera, pooled pre-immune mice sera or anti-E2 AP33 antibodies (10 µg/mL), as positive control for inhibition of HCVpp infection. Cells were harvested at 72 h post-infection and luciferase activity was determined by using the Luciferase Assay System kit (Promega), following the manufacturer’s protocol. The cell lysates were transferred in 96-well white plates and luminescence was measured immediately after addition of the luciferase substrate, using a plate reader Mithras LB940 (Berthold Technologies). Relative light units (RLU) recorded for vaccinated mice sera were normalized to the pre-immune sera corresponding to each group. All experimental conditions were performed twice, in quadruplicates.

Statistics

Intergroup comparisons for the humoral immune response were performed by Wilcoxon rank sum test, with R version 3.2.3. Statistical significance in the analysis of HCV-E2 binding to CD81 by capture ELISA was calculated using Student’s t-test and GraphPad Prism 6 software. Comparisons of HCVpp infection in the neutralization assay between HCV-E2- and control-immunized groups was evaluated using Mann-Whitney test, in GraphPad Prims 6. A P value < 0.05 was considered statistically relevant.

Author contributions

N.B.N., J.L.C. and C.S. conceived the study and analyzed the data. M.O.D performed HCV antigen extraction, purification and functional characterization, N-glycan sequencing and HCVpp neutralization studies. J.L.C, R.B., L.P., A.E., H.S. and S.H made the HCV gene constructs for plant expression and carried out the production of HCV antigen in N. benthamiana. N.Z., D.A. and M.O.D. designed the N-glycan sequencing experiments and interpreted the data. M.O.D and C.I.P. designed the HCVpp neutralization experiments. J.D. contributed reagents and materials. C.S. and

This article is protected by copyright. All rights reserved
A.O. conceived animal experiments. I.C., C.T., E.V and C.S. performed the animal experiments. C.T., S.C. and A.O. analyzed immunology data. N.B.N. and M.O.D wrote the manuscript. J.L.C., C.S., C.I.P, C.T., R.B., J.D., N.Z., D.A., A.E. reviewed the manuscript and provided detailed comments and suggestions for improvement.

Acknowledgment

The research leading to these results has received funding from the EEA Grants 2014-2021, the GreenVac project no. 5/2014 and SmartVac project no. 1/2019.

Conflict of interest statement

The authors have no conflicts of interest to declare.

References

Bartosch, B., Dubuisson, J. and Cosset, F.L. (2003) Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. *The Journal of experimental medicine* **197**, 633-642.

Benyair, R., Ogen-Shtern, N., Mazkereth, N., Shai, B., Ehrlich, M. and Lederkremer, G.Z. (2015) Mammalian ER mannosidase I resides in quality control vesicles, where it encounters its glycoprotein substrates. *Molecular biology of the cell* **26**, 172-184.

Bock, R. (2015) Engineering plastid genomes: methods, tools, and applications in basic research and biotechnology. *Annual review of plant biology* **66**, 211-241.

Caputo, A.T., Alonzi, D.S., Marti, L., Reca, I.B., Kiappes, J.L., Struwe, W.B., Cross, A., Basu, S., Lowe, E.D., Darlot, B., Santino, A., Roversi, P. and Zitzmann, N. (2016) Structures of mammalian ER alpha-glucosidase II capture the binding modes of broad-spectrum iminosugar antivirals. *Proceedings of the National Academy of Sciences of the United States of America* **113**, E4630-4638.

Cavacini, L.A., Kuhrt, D., Duval, M., Mayer, K. and Posner, M.R. (2003) Binding and neutralization activity of human IgG1 and IgG3 from serum of HIV-infected individuals. *AIDS research and human retroviruses* **19**, 785-792.

Chan, H.T. and Daniell, H. (2015) Plant-made oral vaccines against human infectious diseases-Are we there yet? *Plant biotechnology journal* **13**, 1056-1070.
Chan, H.T., Xiao, Y., Weldon, W.C., Oberste, S.M., Chumakov, K. and Daniell, H. (2016) Cold chain and virus-free chloroplast-made booster vaccine to confer immunity against different poliovirus serotypes. *Plant biotechnology journal* **14**, 2190-2200.

Clarke, J.L. and Daniell, H. (2011) Plastid biotechnology for crop production: present status and future perspectives. *Plant molecular biology* **76**, 211-220.

Clarke, J.L., Paruch, L., Dobrica, M.O., Caras, I., Tucureanu, C., Onu, A., Ciulean, S., Stavaru, C., Eerde, A., Wang, Y., Steen, H., Haugslien, S., Petrareanu, C., Lazar, C., Popescu, C.I., Bock, R., Dubuisson, J. and Branza-Nichita, N. (2017) Lettuce-produced hepatitis C virus E1E2 heterodimer triggers immune responses in mice and antibody production after oral vaccination. *Plant biotechnology journal* **15**, 1611-1621.

Cocquerel, L., Duvet, S., Meunier, J.C., Pillez, A., Cacan, R., Wychowski, C. and Dubuisson, J. (1999) The transmembrane domain of hepatitis C virus glycoprotein E1 is a signal for static retention in the endoplasmic reticulum. *Journal of virology* **73**, 2641-2649.

Cocquerel, L., Meunier, J.C., Pillez, A., Wychowski, C. and Dubuisson, J. (1998) A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. *Journal of virology* **72**, 2183-2191.

Cocquerel, L., Wychowski, C., Minner, F., Penin, F. and Dubuisson, J. (2000) Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins. *Journal of virology* **74**, 3623-3633.

Daniell, H., Jin, S., Zhu, X.G., Gitzendanner, M.A., Soltis, D.E. and Soltis, P.S. (2021) Green giant-a tiny chloroplast genome with mighty power to produce high-value proteins: history and phylogeny. *Plant biotechnology journal* **19**, 430-447.

Desombere, I., Fafi-Kremer, S., Van Houtte, F., Pessaux, P., Farhoudi, A., Heydmann, L., Verhoye, L., Cole, S., McKeating, J.A., Leroux-Roels, G., Baumert, T.F., Patel, A.H. and Meuleman, P. (2016) Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. *Hepatology* **63**, 1120-1134.

Dobrica, M.O., Lazar, C., Paruch, L., Skomedal, H., Steen, H., Haugslien, S., Tucureanu, C., Caras, I., Onu, A., Ciulean, S., Branzan, A., Clarke, J.L., Stavaru, C. and Branza-Nichita, N. (2017) A novel chimeric Hepatitis B virus S/preS1 antigen produced in mammalian and plant cells elicits stronger humoral and cellular immune response than the standard vaccine-constituent, S protein. *Antiviral research* **144**, 256-265.
Duvet, S., Cocquerel, L., Pillez, A., Cacan, R., Verbert, A., Moradpour, D., Wychowski, C. and Dubuisson, J. (1998) Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval. *The Journal of biological chemistry* **273**, 32088-32095.

Falkowska, E., Kajumo, F., Garcia, E., Reinus, J. and Dragic, T. (2007) Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. *Journal of virology* **81**, 8072-8079.

Fedorowicz-Stronska, O., Kapusta, J., Czyz, M., Kaczmarek, M. and Pniewski, T. (2016) Immunogenicity of parenterally delivered plant-derived small and medium surface antigens of hepatitis B virus. *Plant cell reports* **35**, 1209-1212.

Feneant, L., Levy, S. and Cocquerel, L. (2014) CD81 and hepatitis C virus (HCV) infection. *Viruses* **6**, 535-572.

Fenouillet, E., Lavillette, D., Loureiro, S., Krashias, G., Maurin, G., Cosset, F.L., Jones, I.M. and Barbouche, R. (2008) Contribution of redox status to hepatitis C virus E2 envelope protein function and antigenicity. *The Journal of biological chemistry* **283**, 26340-26348.

Flint, M., Maidens, C., Loomis-Price, L.D., Shotton, C., Dubuisson, J., Monk, P., Higginbottom, A., Levy, S. and McKeating, J.A. (1999) Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. *Journal of virology* **73**, 6235-6244.

Freeze, H.H. and Kranz, C. (2010) Endoglycosidase and glycoamidase release of N-linked glycans. *Current protocols in molecular biology Chapter 17*, Unit 17 13A.

Gleba, Y., Klimyuk, V. and Marillonnet, S. (2007) Viral vectors for the expression of proteins in plants. *Current opinion in biotechnology* **18**, 134-141.

Goffard, A., Callens, N., Bartosch, B., Wychowski, C., Cosset, F.L., Montpellier, C. and Dubuisson, J. (2005) Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. *Journal of virology* **79**, 8400-8409.

Gonzalez-Grande, R., Jimenez-Perez, M., Gonzalez Arjona, C. and Mostazo Torres, J. (2016) New approaches in the treatment of hepatitis C. *World journal of gastroenterology* **22**, 1421-1432.

Grzyb, K., Czarnota, A., Brzozowska, A., Cieslik, A., Rabalski, L., Tyborowska, J. and Bienkowska-Szewczyk, K. (2016) Immunogenicity and functional characterization of Leishmania-derived hepatitis C virus envelope glycoprotein complex. *Scientific reports* **6**, 30627.

He, W., Xu, W., Xu, L., Fu, K., Guo, W., Bock, R. and Zhang, J. (2020) Length-dependent accumulation of double-stranded RNAs in plastids affects RNA interference efficiency in the Colorado potato beetle. *Journal of experimental botany* **71**, 2670-2677.
Heile, J.M., Fong, Y.L., Rosa, D., Berger, K., Saletti, G., Campagnoli, S., Bensi, G., Capo, S., Coates, S., Crawford, K., Dong, C., Wninger, M., Baker, G., Cousens, L., Chien, D., Ng, P., Archangel, P., Grandi, G., Houghton, M. and Abrignani, S. (2000) Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates. Journal of virology 74, 6885-6892.

Helle, F., Goffard, A., Morel, V., Duverlie, G., McKeating, J., Keck, Z.Y., Foung, S., Penin, F., Dubuisson, J. and Voisset, C. (2007) The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. Journal of virology 81, 8101-8111.

Hotez, P.J., Corry, D.B., Strych, U. and Bottazzi, M.E. (2020) COVID-19 vaccines: neutralizing antibodies and the alum advantage. Nature reviews. Immunology 20, 399-400.

Huang, Z., Chen, Q., Hjelm, B., Arntzen, C. and Mason, H. (2009) A DNA replicon system for rapid high-level production of virus-like particles in plants. Biotechnology and bioengineering 103, 706-714.

Huttner, S., Veit, C., Vavra, U., Schoberer, J., Liebminger, E., Maresch, D., Grass, J., Altmann, F., Mach, L. and Strasser, R. (2014) Arabidopsis Class I alpha-Mannosidases MNS4 and MNS5 Are Involved in Endoplasmic Reticulum-Associated Degradation of Misfolded Glycoproteins. The Plant cell 26, 1712-1728.

Ishiura, S. and Yoshida, T. (2019) Plant-based vaccines for Alzheimer's disease. Proceedings of the Japan Academy. Series B, Physical and biological sciences 95, 290-294.

Lazar, C., Uta, M., Petrescu, S.M. and Branza-Nichita, N. (2017) Novel function of the endoplasmic reticulum degradation-enhancing alpha-mannosidase-like proteins in the human hepatitis B virus life cycle, mediated by the middle envelope protein. Cellular microbiology 19.

Levrero, M. (2006) Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25, 3834-3847.

Li, D., von Schaewen, M., Wang, X., Tao, W., Zhang, Y., Li, L., Heller, B., Hrebikova, G., Deng, Q., Ploss, A., Zhong, J. and Huang, Z. (2016) Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice. Journal of virology 90, 10486-10498.

Liebminger, E., Huttner, S., Vavra, U., Fischl, R., Schoberer, J., Grass, J., Blaukopf, C., Seifert, G.J., Altmann, F., Mach, L. and Strasser, R. (2009) Class I alpha-mannosidases are required for N-glycan processing and root development in Arabidopsis thaliana. The Plant cell 21, 3850-3867.

Marillonnet, S., Thoeringer, C., Kandzia, R., Klimyuk, V. and Gleba, Y. (2005) Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants. Nature biotechnology 23, 718-723.
Masavuli, M.G., Wijesundara, D.K., Torresi, J., Gowans, E.J. and Grubor-Bauk, B. (2017) Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C. *Frontiers in microbiology* **8**, 2413.

Montero-Morales, L. and Steinkellner, H. (2018) Advanced Plant-Based Glycan Engineering. *Frontiers in bioengineering and biotechnology* **6**, 81.

Op De Beeck, A., Voisset, C., Bartosch, B., Ciczora, Y., Cocquerel, L., Keck, Z., Foug, S., Cosset, F.L. and Dubuisson, J. (2004) Characterization of functional hepatitis C virus envelope glycoproteins. *Journal of virology* **78**, 2994-3002.

Osburn, W.O., Snider, A.E., Wells, B.L., Latanich, R., Bailey, J.R., Thomas, D.L., Cox, A.L. and Ray, S.C. (2014) Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. *Hepatology* **59**, 2140-2151.

Owsianka, A., Clayton, R.F., Loomis-Price, L.D., McKeating, J.A. and Patel, A.H. (2001) Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. *The Journal of general virology* **82**, 1877-1883.

Owsianka, A., Tarr, A.W., Juttla, V.S., Lavillette, D., Bartosch, B., Cosset, F.L., Ball, J.K. and Patel, A.H. (2005) Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. *Journal of virology* **79**, 11095-11104.

Pagny, S., Cabanes-Macheteau, M., Gillikin, J.W., Leborgne-Castel, N., Lerouge, P., Boston, R.S., Faye, L. and Gomord, V. (2000) Protein recycling from the Golgi apparatus to the endoplasmic reticulum in plants and its minor contribution to calreticulin retention. *The Plant cell* **12**, 739-756.

Pawlotsky, J.M. (2014) New hepatitis C therapies: the toolbox, strategies, and challenges. *Gastroenterology* **146**, 1176-1192.

Penin, F., Dubuisson, J., Rey, F.A., Moradpour, D. and Pawlotsky, J.M. (2004) Structural biology of hepatitis C virus. *Hepatology* **39**, 5-19.

Pierce, B.G., Keck, Z.Y., Lau, P., Fauvelle, C., Gowthaman, R., Baumert, T.F., Fuerst, T.R., Mariuzza, R.A. and Foug, S.K.H. (2016) Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design. *Proceedings of the National Academy of Sciences of the United States of America* **113**, E6946-E6954.

Pileri, P., Uematsu, Y., Campagnoli, S., Galli, G., Falugi, F., Petracca, R., Weiner, A.J., Houghton, M., Rosa, D., Grandi, G. and Abrignani, S. (1998) Binding of hepatitis C virus to CD81. *Science* **282**, 938-941.

Pniewski, T., Milczarek, M., Wojas-Turek, J., Pajtasz-Piasecka, E., Wietrzyk, J. and Czyz, M. (2018) Plant lyophilisate carrying S-HBsAg as an oral booster vaccine against HBV. *Vaccine* **36**, 6070-6076.
Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J.B., Fausther-Bovendo, H., Wei, H., Aviles, J., Hiatt, E., Johnson, A., Morton, J., Swope, K., Bohorov, O., Bohorova, N., Goodman, C., Kim, D., Pauly, M.H., Velasco, J., Pettitt, J., Olinger, G.G., Whaley, K., Xu, B., Strong, J.E., Zeitlin, L. and Kobinger, G.P. (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. *Nature* **514**, 47-53.

Rath, S. and Devey, M.E. (1988) IgG subclass composition of antibodies to HBsAg in circulating immune complexes from patients with hepatitis B virus infections. *Clinical and experimental immunology* **72**, 164-167.

Reed, K.E. and Rice, C.M. (2000) Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. *Current topics in microbiology and immunology* **242**, 55-84.

Sainsbury, F., Thuenemann, E.C. and Lomonossoff, G.P. (2009) pEAQ: versatile expression vectors for easy and quick transient expression of heterologous proteins in plants. *Plant biotechnology journal* **7**, 682-693.

Saxena, P., Thuenemann, E.C., Sainsbury, F., Lomonossoff, G.P. (2016) Virus-Derived Vectors for the Expression of Multiple Proteins in Plants. In: Recombinant Proteins from Plants: Methods and Protocols. (J. MacDonald, I.K., R. Menassa eds ed) pp. pp. 39– 54. New York: Springer.

Schillberg, S., Raven, N., Spiegel, H., Rasche, S. and Buntru, M. (2019) Critical Analysis of the Commercial Potential of Plants for the Production of Recombinant Proteins. *Frontiers in plant science* **10**, 720.

Schoberer, J., Konig, J., Veit, C., Vavra, U., Liebminger, E., Botchway, S.W., Altmann, F., Kriechbaumer, V., Hawes, C. and Strasser, R. (2019) A signal motif retains Arabidopsis ER-alpha-mannosidase I in the cis-Golgi and prevents enhanced glycoprotein ERAD. *Nature communications* **10**, 3701.

Schwarz, F. and Aebi, M. (2011) Mechanisms and principles of N-linked protein glycosylation. *Current opinion in structural biology* **21**, 576-582.

Shimotohno, K., Tanji, Y., Hirowatari, Y., Komoda, Y., Kato, N. and Hijikata, M. (1995) Processing of the hepatitis C virus precursor protein. *Journal of hepatology* **22**, 87-92.

Siriwatthananon, K., Manopwisedjaroen, S., Kanjanasirirat, P., Budi Purwono, P., Rattanapisit, K., Shanmugaraj, B., Smith, D.R., Borwornpinyo, S., Thitithanyanont, A. and Phoolcharoen, W. (2020) Development of Plant-Produced Recombinant ACE2-Fc Fusion Protein as a Potential Therapeutic Agent Against SARS-CoV-2. *Frontiers in plant science* **11**, 604663.

Strasser, R. (2016) Plant protein glycosylation. *Glycobiology* **26**, 926-939.

Urbanowicz, R.A., Wang, R., Schiel, J.E., Keck, Z.Y., Kerzic, M.C., Lau, P., Rangarajan, S., Garagusi, K.J., Tan, L., Guest, J.D., Ball, J.K., Pierce, B.G., Mariuzza, R.A., Foung, S.K.H. and Fuerst, T.R. (2019)
Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells. *Journal of virology* 93.

van Eerde, A., Gottschamel, J., Bock, R., Hansen, K.E.A., Munang'andu, H.M., Daniell, H. and Liu Clarke, J. (2019) Production of tetravalent dengue virus envelope protein domain III based antigens in lettuce chloroplasts and immunologic analysis for future oral vaccine development. *Plant biotechnology journal* 17, 1408-1417.

van Eerde, A., Varnai, A., Jameson, J.K., Paruch, L., Moen, A., Anonsen, J.H., Chylenski, P., Steen, H.S., Heldal, I., Bock, R., Eijsink, V.G.H. and Liu-Clarke, J. (2020) In-depth characterization of Trichoderma reesei cellobiohydrolase TrCel7A produced in Nicotiana benthamiana reveals limitations of cellulase production in plants by host-specific post-translational modifications. *Plant biotechnology journal* 18, 631-643.

Walker, M.R., Eltahla, A.A., Mina, M.M., Li, H., Lloyd, A.R. and Bull, R.A. (2020) Envelope-Specific IgG3 and IgG1 Responses Are Associated with Clearance of Acute Hepatitis C Virus Infection. *Viruses* 12.

Walker, M.R., Leung, P., Eltahla, A.A., Underwood, A., Abayasingam, A., Brasher, N.A., Li, H., Wu, B.R., Maher, L., Luciani, F., Lloyd, A.R. and Bull, R.A. (2019) Clearance of hepatitis C virus is associated with early and potent but narrowly-directed, Envelope-specific antibodies. *Scientific reports* 9, 13300.

WHO (2019) Hepatitis C, https://www.who.int/news-room/fact-sheets/detail/hepatitis-c.

Wong-Arce, A., Gonzalez-Ortega, O. and Rosales-Mendoza, S. (2017) Plant-Made Vaccines in the Fight Against Cancer. *Trends in biotechnology* 35, 241-256.

**Supporting information**

Supporting figures: **Figure S1** CD81 binding of the HCV-E2 antigen produced in *N. benthamiana*

Supporting experimental procedures: Methods S1, Methods S2

**Figure S1** CD81 binding of the HCV-E2 antigen produced in *N. benthamiana*. Samples from the HCV-E2 antigen expressed in *N. benthamiana* leaves and representing different purification steps (Eluate: eluted from GNA column, Dialysed: dialysed against diluted PBS, Speed-vac: speed-vacuum concentrated) were incubated with GST-fused CD81-LEL that had been adsorbed onto glutathione-sepharose resin. Both input and CD81-bound samples were subjected to immunoblotting using anti-E2 3/11 antibodies.
**Methods S1: Vacuum concentration of antigen samples**

The plant-produced HCV-E2 antigen eluted from the GNA lectin column was subjected to a concentration step in order to be loaded on the HiLoad 16/600 Superdex 200 pg column (GE Healthcare). To test alternative sample concentration procedures to Amicon, E2-containing fractions were pooled and dialysed against diluted buffer (PBS containing 0.1% Triton X-100, diluted 1:60 with water) followed by 60-fold concentration using a Savant SpeedVac SPD120 Vacuum Concentrator, at 50°C.

**Methods S2: CD81 pull-down assay**

The recombinant CD81-LEL-GST (10 µg) was adsorbed onto 50 µL glutathione-sepharose beads (GE Healthcare), as published (Clarke et al., 2017). HCV-E2 antigen samples were retained at different stages of purification from *N. benthamiana* leaves and mixed with PBS to a final volume of 1 mL. Protein samples were further incubated with the CD81-adsorbed Sepharose beads, at 4°C, under gentle agitation. The beads were washed five times with PBS and bound proteins were separated by SDS-PAGE. The E2 protein was detected by western blot analysis, as described in Experimental procedures.

**Figure legends**

**Figure 1** Production of the HCV-E2 antigen in HEK392T and *N. benthamiana*. (a) Schematic representation of the T-DNA of the pEAQ-HT-DEST1-derived vector for HCV-E2 expression in *N. benthamiana*. GoI, gene of interest (i.e., the E2 coding region preceded by the last 32 E1 codons). RB/LB, right and left borders; 5′ UTR and 3′ UTR, 5′ and 3′ untranslated regions derived from Cowpea mosaic virus (CPMV); P 35S, Cauliflower mosaic virus (CaMV) 35S promoter; T 35S, CaMV 35S terminator; P Nos, nopaline synthase promoter; T Nos, nopaline synthase terminator; P19, suppressor of gene silencing; NPT II, neomycin phosphotransferase II gene conferring kanamycin resistance. (b) Lysates from HEK293T cells expressing HCV-E2 resulted from processing of the E1E2 polypeptide or the HCV-E2 protein (left panel), and lysates from HEK293T cells (HEK) or *N. benthamiana* leaves (*N.b.*) expressing HCV-E2 or the control vector (right panel), harvested at 7 dpi were subjected to immunoblotting and detection with anti-E2 3/11 Abs.
**Figure 2** Glycosylation characteristics of the HCV-E2 antigen produced in *N. benthamiana*. Lysates from HEK293T cells (HEK) and *N. benthamiana* leaves (N.b.) expressing HCV-E2 were subjected to Endo H digestion (+) or left untreated (-) followed by western blotting. Glycosylated (gp) and deglycosylated (p) polypeptides were detected using anti-E2 3/11 Abs.

**Figure 3** Purification of the HCV-E2 antigen produced in *N. benthamiana*. (a) Lysates from *N. benthamiana* leaves expressing the HCV-E2 antigen were resolved by SDS-PAGE and stained with Coomassie Instant Blue (left panel) before loading onto a GNA lectin column. Samples from the input lysate, the unbound flow-through and the methyl-α-D-mannopyranoside-eluted fractions were subjected to immunoblotting and detection with anti-E2 3/11 Abs (right panel). (b) The positive GNA fractions were concentrated and loaded onto a HiLoad 16/600 Superdex 200 pg column. The HCV-E2 protein was detected in the new collected fractions by western blotting using anti-E2 3/11 Abs. (c) The HCV-E2 antigen eluted from the HiLoad 16/600 Superdex 200 pg column was concentrated on an Amicon-50 ultra filter, subjected to SDS-PAGE and either stained with Coomassie Instant Blue (left panel) or detected by western blot with anti-E2 3/11 antibodies, alongside the HEK293T-E1E2 control purified on GNA lectin (right panel). (d) Amount, recovery yield and purity of the HCV-E2 antigen in the *N. benthamiana* crude extract (input) and at each purification step were determined by using ELISA. The recovery yields are shown as percentages of HCV-E2 antigen from the amount recovered at the previous purification step. FW, Fresh Weight; ND, Not Determined.

**Figure 4** N-glycan profile of HCV-E2 produced in *N. benthamiana* and mammalian cells. GNA-purified HCV-E2 protein from *N. benthamiana* leaves (black) or FreeStyle 293-F cells (red) was subjected to in gel-digestion with either PNGase F (a) or Endo H (b). The released N-linked glycans were fluorescently labeled with 2-AA, purified and analysed by NP-HPLC. Representative chromatograms are shown. Glucose units (GU) corresponding to a labeled glucose oligomer ladder are also indicated. GU were calculated for each peak and glycan structures were assigned. The percentages of glycan distribution were calculated for each *N. benthamiana*- and FreeStyle293-F-produced E2 glycoprotein (c), and plotted (d). The data represent means ± SD from two independent experiments for each of the PNGase F and Endo H digestions.

**Figure 5** Analysis of binding of the plant-produced HCV-E2 antigen to the CD81 receptor. HCV-E2 binding to the CD81 receptor was evaluated by ELISA. 96-well plates were coated with either
the recombinant large extracellular loop of human CD81 (CD81-LEL) or anti-E2 3/11 Abs (rat). The CD81-coated wells were incubated with purified samples from *N. benthamiana* control plants (CD81 - HCV-E2) or from plants expressing HCV-E2 antigen (CD81 + HCV-E2). The purified HCV-E2 was pre-incubated with anti-E2 3/11 Abs (CD81 + HCV-E2 + 3/11), as indicated. The anti-E2 3/11-coated wells were incubated with purified samples from *N. benthamiana* control plants (3/11 - HCV-E2) or from plants expressing HCV-E2 antigen (3/11 + HCV-E2). HCV-E2 protein left after binding on CD81-coated wells was also added onto the 3/11-coated wells (3/11 + HCV-E2 + CD81-unbound). Anti-E2 H53 (mouse) and anti-mouse-HRP Abs were used for detection. Mean RLU values and standard deviations are represented. Statistical significance was calculated using Student’s t-test (*) *, P<0.05; **, P<0.01.

**Figure 6** Humoral immune response to administered tobacco-based HCV-E2 antigen as analyzed in sera of immunized mice. Groups of five mice were immunized with adjuvanted *N. benthamiana*-produced HCV-E2 protein (1), adjuvanted *N. benthamiana* control protein (2) or Al(OH)₃ adjuvant only (3) three times, at 14 day intervals. IgM (a), IgG (b) and IgG1 (c) endpoint titers at days 0, 27 and 49 were calculated based on a 4-parameter logistic regression curve fitted to a pool of immune sera, as the reciprocal sample dilution that would result in three times baseline + standard error as derived from the internal standard curve by multiplication. Individual titers are presented and data are summarized as Tukey plots. Ab titers were compared by using the Wilcoxon rank sum test. *, comparison between groups at the same time point (*, P<0.05; **, P<0.01), #, time points at days 27 and 49 compared to day 0 (#, P<0.05; ##, P<0.01), &, time point at day 49 compared to day 27, (&, P<0.05; &&, P<0.01).

**Figure 7** Neutralization of HCVpp infection. Huh7 cells were infected with pseudo-particles (pp) containing a luciferase gene and the HCV-1a E1E2 envelope (+ HCVpp), the VSV-G envelope (+VSV-G) or no envelope (-HCVpp/-VSV-Gpp), produced in HEK293T cells. HCVpp (a) and VSV-Gpp (b) infections were performed in the presence of day 56-serum from individual mice immunized with *N. benthamiana*-produced HCV-E2, control protein (five mice/group) or pooled preimmune sera (dilution 1:25). Anti-E2 AP33 Abs (10 µg/mL) were used as positive control for inhibition of HCVpp infection. The luciferase activity was determined in each sample. Black dots and squares represent RLU values for individual mice calculated as average percentages from the pooled preimmune serum-treated HCVpp/VSV-Gpp corresponding to each animal group. A representative experiment is shown. Black triangles represent control RLU values as percentages.
from untreated HCVpp/VSV-Gpp. Black bars indicate the means of the shown values for each condition. The P value between the HCV-E2-immunized and the control-immunized groups was determined using the Mann-Whitney test. *, P<0.05.
HCV-E2 – *N. benthamiana*

(a) Eluted fractions – GNA lectin

(b) Eluted fractions – SEC

(c) Purified HCV-E2 – *N. benthamiana*

(d) Purification of HCV-E2 extracted from *N. benthamiana*

| Sample                  | Amount μg HCV-E2 / g FW | Recovery yield | Purity (%) |
|-------------------------|-------------------------|----------------|------------|
| Input (crude extract)   | 5-20                    | -              | 0.004-0.016|
| GNA lectin              | 4-16                    | 80%            | 2-3        |
| Amicon 50 kDa           | 0.8-3                   | 18% (soluble fraction only) | ND        |
| SEC                     | 0.4-1.5                 | 50%            | 15-25      |
This article is protected by copyright. All rights reserved

[Graph showing RLU values for different conditions]

Coating: 3/11  CD81  3/11  CD81  3/11  CD81  3/11
HCV-E2:   -    -    +    +    +    +    -
HCV-E2 + 3/11: -    -    -    +    -    -    -
CD81-unbound: -    -    -    -    -    -    +

pbi_13631_f5.tif
